Holen Sie sich die Stockscreener-App
128.31
0.06%
0.115
Blueprint Medicines Corp Aktie (BPMC) Neueste Nachrichten
Blueprint Medicines (BPMC) Downgraded by Wells Fargo Amid Acquis - GuruFocus
BPMC: Wells Fargo Downgrades Blueprint Medicines, Lowers Price Target | BPMC Stock News - GuruFocus
Sanofi, Blueprint Medicines filed HSR June 9 - MLex
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, SVT, SSBK on Behalf of Shareholders - GlobeNewswire Inc.
Blueprint Medicines’ SWOT analysis: stock poised for growth amid Sanofi acquisition - Investing.com
Blueprint Medicines (BPMC) Showcases Groundbreaking Data on Syst - GuruFocus
Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses - PR Newswire
Blueprint Medicines Stock Experiences Wild Intraday Swing, Closes Flat Amid Strong Momentum - Daily Chhattisgarh News
Blueprint Medicines stock hits all-time high of $128.3 By Investing.com - Investing.com Canada
Blueprint Medicines stock hits all-time high of $128.3 - Investing.com
Sanofi to Buy Immunology Biotech Blueprint for $9.1 Billion - MSN
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta - Benzinga
Blueprint Medicines (BPMC): Morgan Stanley Raises Price Target | BPMC Stock News - GuruFocus
UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal - TradingView
Citigroup Upgrades Blueprint Medicines (BIT:1BPMC) - Nasdaq
Sanofi to acquire Blueprint Medicines for about $9.1B - Drug Store News
Blueprint Medicines (BPMC) Target Price Raised by UBS Analyst | - GuruFocus
Blueprint Medicines (BPMC) Target Price Raised by UBS Analyst | BPMC Stock News - GuruFocus
Blueprint Medicines (BPMC) Sees Price Target Increase Amid Acquisition News | BPMC Stock News - GuruFocus
Sanofi to buy Blueprint Medicines for $9.1B - MSN
Blueprint Medicines (BPMC) Target Price Increased Following Acqu - GuruFocus
Blueprint Medicines (BPMC) Target Price Increased Following Acquisition News | BPMC Stock News - GuruFocus
Stephens & Co. Downgrades Blueprint Medicines (BPMC) to Equal Weight, Cuts PT - Insider Monkey
Citizens JMP Downgrades Blueprint Medicines (BPMC) to Market Perform - Insider Monkey
Sanofi to Buy Blueprint for $9.1 Billion Equity Value - MSN
Nasdaq Today Blueprint Medicines Reclassified Kalkine - Kalkine Media
BPMC Stock Upgraded: Citigroup Raises Price Target Significantly - GuruFocus
BPMC Stock Upgraded: Citigroup Raises Price Target Significantly | BPMC Stock News - GuruFocus
Citi upgrades Blueprint Medicines stock rating after Sanofi acquisition - Investing.com
Blueprint Medicines (BPMC) Sees Upgrade and Acquisition by Sanof - GuruFocus
Blueprint Medicines Stock Surges as Sanofi Announces $9.5 Billion Acquisition - MSN
BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines CorporationBPMC - Business Wire
Blueprint Medicines Corporation (BPMC) Downgraded at TD Cowen - Insider Monkey
Wolfe Research Lowered Blueprint Medicines Corporation (BPMC) from Outperform to Peer Perform - Insider Monkey
Blueprint Medicines (BPMC) Downgraded Following Acquisition News - GuruFocus
Blueprint Medicines (BPMC) Downgraded Following Acquisition News | BPMC Stock News - GuruFocus
Blueprint Medicines downgraded to Neutral from Buy at Guggenheim - TipRanks
Guggenheim Downgrades Blueprint Medicines to Neutral From Buy, Price Target is $132 - marketscreener.com
Sanofi to acquire Blueprint for up to $9.5B - Pharma Voice
Blueprint Medicines (BPMC) Downgraded by JMP Securities | BPMC S - GuruFocus
Blueprint Medicines (BPMC) Downgraded by JMP Securities | BPMC Stock News - GuruFocus
Blueprint Medicines (BPMC) Receives Downgrade from Stephens & Co - GuruFocus
Blueprint Medicines (BPMC) Receives Downgrade from Wolfe Research | BPMC Stock News - GuruFocus
Wolfe Downgrades Blueprint Medicines to Peer Perform From Outperform - marketscreener.com
Blueprint Medicines (BPMC) Downgraded Following Acquisition Deal - GuruFocus
Stephens Downgrades Blueprint Medicines to Equalweight From Overweight, Adjusts PT to $135 From $150 - marketscreener.com
JPMorgan Downgrades Blueprint Medicines to Neutral From Overweight, Adjusts PT to $129 From $130 - marketscreener.com
Sanofi to acquire US biotech firm Blueprint for up to $9.5bn - World Pharmaceutical Frontiers
Blueprint Medicines (BPMC) Downgraded Amid Sanofi Acquisition Pr - GuruFocus
Blueprint Medicines (BPMC) Downgraded Amid Sanofi Acquisition Proposal | BPMC Stock News - GuruFocus
Citizens JMP downgrades Blueprint Medicines stock on Sanofi acquisition - Investing.com
TD Cowen cuts Blueprint Medicines stock rating following Sanofi acquisition By Investing.com - Investing.com Nigeria
Citizens JMP downgrades Blueprint Medicines stock on Sanofi acquisition By Investing.com - Investing.com India
JPMorgan downgrades Blueprint Medicines stock after Sanofi acquisition By Investing.com - Investing.com Nigeria
TD Cowen cuts Blueprint Medicines stock rating following Sanofi acquisition - Investing.com
0.34%
7.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):